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ODS: Data from recently published outcome studies was
incorporated into TreeAge software to construct the one-
year decision analysis model. The primary cost drivers
thought to influence cost-effectiveness were complicated
GI bleeds, hospitalizations, and symptomatic ulcers, as
well as differences in renal toxicity, dyspepsia, anemia,
hypertension and edema. Sensitivity analysis was per-
formed on all major indices based on variations in results
found in reviewed studies. RESULTS: Overall rates of
adverse events were similar for all agents (75% NSAIDs,
72% celecoxib, 78% rofecoxib), however celecoxib was
associated with less events relating to primary cost driv-
ers. These differences are attributed mainly to variances
among adverse event probabilities for hypertension and
edema (NSAIDs 4.7%, 4.4%, celecoxib 1.6%, 2.9%, rofe-
coxib 6.4%, 6.3%, respectively). Cost of drug treatment
per year for NSAIDs, celecoxib, and rofecoxib are $36.00,
$466.00, and $482.00, respectively, based on Federal
Supply Schedule (FSS) pricing. CONCLUSIONS: Based
on preliminary data, therapy with COX-2 inhibitors does
not appear to be cost-effective to prescribe for all os-
teoarthritic patients within the VA Health care System.
Results may be extrapolated to other health care settings
assuming medical costs are similar.
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OBJECTIVES: To evaluate the changes in patient utility
with treatment of active rheumatoid arthritis (RA) with
leflunomide (LEF), placebo (PBO) or methotrexate
(MTX). METHODS: A 52 week multicenter double-
blind controlled trial comparing treatment with lefluno-
mide, methotrexate or placebo in patients with active
rheumatoid arthritis was used to derive patient utilities.
Short Form 36 (SF-36) data were used to generate utility
scores using the algorithm developed by Brazier et al
(1999). These utilities would reflect general population
values and would not be specific to an RA population.
Inclusion in the utility analysis required consistent SF-36
responses, a baseline and at least one other completed as-
sessment, and valid responses to derive the SF-6D utili-
ties. The area under the curve was calculated for com-
pleters and the intent-to-treat population in order to
estimate incremental quality adjusted life years (QALYs)
for the treatments. RESULTS: The clinical study popula-
tion consisted of 182 LEF, 180 MTX and 118 PBO pa-
tients. The population used for the utility analysis con-
sisted of 165 LEF, 164 MTX and 114 (PBO). Baseline
utility values were comparable between groups, ranging
from 0.622 to 0.637. Incremental QALYs gained for
completers was statistically significantly superior for LEF
over PBO (p  0.0317) and MTX (p  0.0130). Treat-
ment with LEF resulted in an incremental gain of 0.084
QALYs, starting from a baseline of 0.622. Similar results
were seen with the intent-to-treat population. CONCLU-
SIONS: Treatment of RA with LEF statistically improves
patient health state utility values and QALY gain over
MTX and PBO.
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OBJECTIVES: To evaluate the stability and discrimina-
tive ability of direct and indirect measures of utility in a
population of rheumatoid arthritis patients. METHODS:
Clinical trial data was used to compare the stability of di-
rect measures of utility (SG and VAS) to that from an in-
direct approach to utility development (SF-6D). SF-36
data were transformed to the SF-6D utility using the al-
gorithm developed by Brazier et al.(1999) based on val-
ues of the general UK population. These data were com-
pared to SG and VAS data collected in the same trial.
Ability to discriminate across functional classes and vari-
ance around point estimates was examined. RESULTS:
The SF-6D generated utilities that were consistently
lower than the directly elicited SG and were closer to the
VAS valuations. The standard deviations, however, were
consistently smaller.
CONCLUSIONS: The indirect measure of utility (SF-6D)
was more stable in terms of variance of parameter esti-
mates and was able to discriminate across functional
classes. The reduced variance around these estimates en-
hances statistical testing and accurately reflects changes
experienced by the patient.
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BACKGROUND: Regence BlueShield, a 1.2 million-
member Washington health plan currently requires prior
Baseline Week 24 Week 52
SG 0.7759 (0.2399) 0.8684 (0.1850) 0.8794 (0.1858)
VAS 0.5902 (0.1942) 0.7425 (0.1623) 0.7701 (0.1629)
SF-6D 0.6287 (0.1290) 0.7323 (0.1109) 0.7443 (0.1089)
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authorization for coverage of COX-2 inhibitors. Evi-
dence-based coverage criteria limit these drugs to mem-
bers who are at moderate to high-risk of NSAID-induced
GI events. Regence was interested in the economic impact
of the COX-2s. However, cost-effectiveness data were
not available from the manufacturers. OBJECTIVES: 1)
To evaluate the cost impact of COX-2 inhibitors on a
managed care population. 2) To determine the appropri-
ateness (in economic terms) of the prior authorization
criteria. METHODS: The VIGOR trial assessed the de-
velopment of clinically important ulcer events and com-
plicated upper GI events, including perforation, obstruc-
tion, and bleeding (POBs), in patients using either
rofecoxib or naproxen. Using the same DRGs and ICD9
codes in the VIGOR study, Regence obtained their own
patient data for these events in the year 2000. The num-
ber needed to treat (NNT), cost to prevent one clinically
significant upper GI event, and the cost to prevent one
complicated upper GI event (needing hospitalization)
were calculated from the data presented in the VIGOR
trial. RESULTS: The average COX-2 drug cost per pa-
tient per year is $1,100. The cost to prevent one clinically
significant NSAID-induced upper GI event is $46,000,
and the cost to prevent one NSAID-induced complicated
upper GI event requiring hospitalization, is $137,500. In
the year 2000, 443 Regence members were hospitalized
for an upper GI POB with a total cost of nearly $4 mil-
lion (average $9030 per hospitalization). CONCLU-
SIONS: In the absence of complete cost-effectiveness
data, a large health plan conducted a simple, yet very use-
ful cost impact analysis to support and inform drug pol-
icy for COX-2 inhibitors. The cost per hospitalization
avoided is much higher than the actual hospitalization
costs. This supported the Regence decision to limit cover-
age of COX-2 inhibitors to a moderate to high-risk popu-
lation.
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IMPORTANT ISSUES IN NUMBER NEEDED TO 
TREAT ANALYSIS IN OSTEOPOROSIS 
TREATMENT
Kemner JE
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Number Needed to Treat (NNT) is calculated in clinical
trials by taking the inverse of the difference in absolute
risk in the placebo group from the treatment group. It
captures how many people would need to receive a treat-
ment to prevent a disease or event. OBJECTIVES: To de-
termine the roles of treatment efficacy and population
characteristics in Number Needed to Treat (NNT) calcu-
lations within randomized clinical trials of osteoporosis
pharmacological agents. METHODS: Data were col-
lected from publications of three major clinical trials of
pharmacological osteoporosis agents. Trials valuated
were the Multiple Outcomes of Raloxifene Evaluation
(MORE), Fracture Intervention Trial 1&2 (FIT) which
evaluated Alendronate, and Vertebral Efficacy with
Risedronate Therapy (VERT). NNT, mean age, baseline
Bone Mineral Density (BMD) at spine, baseline vertebral
fracture rate, vertebral fracture rates in the placebo and
treatment groups, and relative risk reductions were ab-
stracted. RESULTS: The Number Needed to Treat not
only varied among different agents but also in different
populations where the same treatment was used. The
MORE trial reported two NNTs. The “MORE 1” trial,
where few participants had a prevalent vertebral fracture
(11%), found an NNT of 46 while “MORE 2”, where
most participants had a prevalent vertebral fracture
(88%), found an NNT of 16. FIT1, where all participants
had prevalent vertebral fractures, reported an NNT of 15
while FIT2, no participants had a prevalent fracture, re-
ported an NNT of 60. The VERT trial’s NNT was calcu-
lated to be 20 using the above method. VERT had an
80% prevalent vertebral fracture rate. CONCLUSION:
Variation in NNT is due to the different characteristics
like placebo fracture rates as well as treatment efficacy. If
one compares the trials with the most similar placebo
group fracture rates, “MORE2”, FIT1, and VERT, the
Number Needed to Treat is quite similar. Dissimilar pop-
ulation characteristics as opposed to differences in treat-
ment efficacy can be responsible for differences in NNT.
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OBJECTIVE: The importance of assessing fatigue in
rheumatoid arthritis (RA) has been confirmed in numer-
ous studies. Several instruments are available to assess fa-
tigue, however, the psychometric properties of most have
been determined in various populations other than RA
and the instruments tend to measure different aspects of
fatigue. The objective of this study was to assess the per-
formance of two fatigue instruments, one was developed
in the RA population and the other in a nondisease-spe-
cific population. METHODS: This study is an ongoing
prospective, multi-center, observational study conducted
to document long-term functional, clinical, humanistic
and economic outcomes, and treatment patterns in pa-
tients with new onset rheumatoid arthritis. Two fatigue
instruments were used to assess RA patients: The Func-
tional Assessment of Chronic Illness Therapy-Fatigue
Subscale (FACIT-F), an instrument used primarily in on-
cology populations, and the Multidimensional Assess-
ment of Fatigue (MAF), developed in an RA population.
MAF measures four dimensions of fatigue (severity, dis-
tress, degree of interference in daily activities, and tim-
ing). At baseline, patients were requested to complete
both the 16-item, MAF and the 13-item, FACT-F via tele-
phone interview. Using baseline data only, the correlation
between the MAF and the FACIT-F was tested in 133 pa-
tients with early RA (signs and symptoms 3 months and
